Viral oncogenes, viruses, and cancer: a third-generation sequencing perspective on viral integration into the human genome.

PacBio cancer sequencing nanopore third generation sequencing viral integration

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 07 11 2023
accepted: 06 12 2023
medline: 8 1 2024
pubmed: 8 1 2024
entrez: 8 1 2024
Statut: epublish

Résumé

The link between viruses and cancer has intrigued scientists for decades. Certain viruses have been shown to be vital in the development of various cancers by integrating viral DNA into the host genome and activating viral oncogenes. These viruses include the Human Papillomavirus (HPV), Hepatitis B and C Viruses (HBV and HCV), Epstein-Barr Virus (EBV), and Human T-Cell Leukemia Virus (HTLV-1), which are all linked to the development of a myriad of human cancers. Third-generation sequencing technologies have revolutionized our ability to study viral integration events at unprecedented resolution in recent years. They offer long sequencing capabilities along with the ability to map viral integration sites, assess host gene expression, and track clonal evolution in cancer cells. Recently, researchers have been exploring the application of Oxford Nanopore Technologies (ONT) nanopore sequencing and Pacific BioSciences (PacBio) single-molecule real-time (SMRT) sequencing in cancer research. As viral integration is crucial to the development of cancer via viruses, third-generation sequencing would provide a novel approach to studying the relationship interlinking viral oncogenes, viruses, and cancer. This review article explores the molecular mechanisms underlying viral oncogenesis, the role of viruses in cancer development, and the impact of third-generation sequencing on our understanding of viral integration into the human genome.

Identifiants

pubmed: 38188304
doi: 10.3389/fonc.2023.1333812
pmc: PMC10768168
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1333812

Informations de copyright

Copyright © 2023 Ye, Wang, Bu, Luo, Deng, Zhang and Yin.

Déclaration de conflit d'intérêts

WD and SY hold equity in Yihui Bio, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Ruichen Ye (R)

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, United States.
Einstein Pathology Single-cell & Bioinformatics Laboratory, Bronx, NY, United States.
Stony Brook University, Stony Brook, NY, United States.

Angelina Wang (A)

Tufts Friedman School of Nutrition, Boston, MA, United States.

Brady Bu (B)

Horace Mann School, Bronx, NY, United States.

Pengxiang Luo (P)

Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Wenjun Deng (W)

Clinical Proteomics Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

Xinyi Zhang (X)

Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Shanye Yin (S)

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, United States.
Einstein Pathology Single-cell & Bioinformatics Laboratory, Bronx, NY, United States.

Classifications MeSH